TheSUBWAY.com Announces Investment Opinion on Destiny Media Technologies, Inc., Vertical Computer Systems Inc., XO Communications, Inc., California Amplifier, Inc. and StemCells, Inc

Business Wire, June 8, 2001

Sales for the fiscal year ended March 3, 2001 were $124,979,000 as compared to $86,417,000 for fiscal year 2000. Net income for fiscal year 2001 was $5,209,000, or $0.37 per diluted share, as compared to a net loss of $5,064,000, or $0.42 per share for fiscal year 2000. Fred Sturm, Chief Executive Officer, commented: 'I am pleased to report that during fiscal 2001 the Company achieved significant growth in revenue and earnings. These results were achieved through an ongoing program to develop cost effective and innovative products for our key markets, which enabled us to build stronger relationships with our customer base.'

StemCells, Inc. (Nasdaq:STEM) Previous Close: Up 66 % to $5.43 on vol. 4,374,600 Shares: ACCUMULATE ON DIP

StemCells, Inc. (Nasdaq:STEM) announced the issuance of two U.S. patents that further their proprietary position in the neural and pancreatic programs, respectively. The first, a process patent, covers a novel method to separate neural stem cells for growth in culture. 'This method allows us to expand and harvest a significantly greater number of viable cells than was previously possible. It should help us to develop a more efficient manufacturing process for human neural stem cells and to scale up production of cells as we continue our preclinical research and development,' said Dr. Nobuko Uchida, inventor and Director of Neural Stem Cell Research.

The second patent covers a unique murine model useful for identifying stem/progenitor cells for the pancreas and liver. 'This newly patented work is important enabling technology that may provide a stepping stone to the discovery of the stem cell capable of regenerating the pancreas or liver,' explains Dr. Ann Tsukamoto, VP Scientific Operations at StemCells Inc. StemCells owns or has exclusive licenses to twenty-five issued U.S. patents in the neural stem cell field, as well as fifteen U.S. applications (including two that have been allowed) and pending foreign counterparts.

StemCells Inc. is a biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver, and pancreas. The Company's stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury.

"The broader market enticed buyers in the drug, transportation, retail, and chemical arenas, while financial, financial service, oil service, utility, and biotech issues showed modest declines. Volume continued light, with 1.1 billion shares changing hands on the New York Stock Exchange, while 1.65 billion shares were exchanged on the Nasdaq Stock Market. Breadth turned positive, with advancing issues edging declining issues by 16 to 15 on the NYSE, and by 21 to 16 on the Nasdaq," stated Peter Antipatis. More is available at http://www.TheSUBWAY.com.

About TheSubway.com

TheSubway.com, a wholly owned online asset of Capital Research Group, Inc. (CRG) was developed solely for experienced, risk tolerant investors. Subscribers to TheSubway.com receive daily market commentary reports for select companies trading on various markets. Sophisticated investors are also able to receive for free, select, rare research reports and investor kits on up and coming emerging companies while they are still not widely known.